This study is accepting new patients by invitation only

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

a study on Alopecia Areata

Summary

Eligibility
for people ages 18-65 (full criteria)
Location
at Irvine, California and other locations
Dates
study started
estimated completion

Description

Summary

The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata.

Official Title

A Multicenter, Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

Keywords

Alopecia Areata, Alopecia, CTP-543

Eligibility

You can join if…

Open to people ages 18-65

- Have completed 24 weeks of treatment in a previous qualifying CTP-543 clinical trial

You CAN'T join if...

  • Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or untreated actinic keratosis
  • Females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study medication
  • Donation of blood at any point throughout the study and for 30 days after last dose of study medication

Locations

  • University of California, Irvine
    Irvine California 92697 United States
  • Dermatology Research Associates
    Los Angeles California 90045 United States

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
Concert Pharmaceuticals
ID
NCT03898479
Phase
Phase 2/3 Alopecia Areata Research Study
Study Type
Interventional
Participants
Expecting 1000 study participants
Last Updated